ES2837487T3 - Métodos para producir células HLA-G modificadas - Google Patents

Métodos para producir células HLA-G modificadas Download PDF

Info

Publication number
ES2837487T3
ES2837487T3 ES18211100T ES18211100T ES2837487T3 ES 2837487 T3 ES2837487 T3 ES 2837487T3 ES 18211100 T ES18211100 T ES 18211100T ES 18211100 T ES18211100 T ES 18211100T ES 2837487 T3 ES2837487 T3 ES 2837487T3
Authority
ES
Spain
Prior art keywords
cell
cells
hla
genetically modified
ehla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18211100T
Other languages
English (en)
Spanish (es)
Inventor
Basil Hantash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serina Therapeutics Inc
Original Assignee
Agex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agex Therapeutics Inc filed Critical Agex Therapeutics Inc
Application granted granted Critical
Publication of ES2837487T3 publication Critical patent/ES2837487T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
ES18211100T 2012-07-31 2013-07-30 Métodos para producir células HLA-G modificadas Active ES2837487T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261677739P 2012-07-31 2012-07-31

Publications (1)

Publication Number Publication Date
ES2837487T3 true ES2837487T3 (es) 2021-06-30

Family

ID=50028654

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18211100T Active ES2837487T3 (es) 2012-07-31 2013-07-30 Métodos para producir células HLA-G modificadas
ES13825511T Active ES2716577T3 (es) 2012-07-31 2013-07-30 Células HLA-G modificadas y métodos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13825511T Active ES2716577T3 (es) 2012-07-31 2013-07-30 Células HLA-G modificadas y métodos

Country Status (10)

Country Link
US (4) US9714280B2 (https=)
EP (4) EP2880054B1 (https=)
JP (4) JP6297559B2 (https=)
KR (4) KR101923632B1 (https=)
CN (2) CN113151179A (https=)
AU (2) AU2013296564C1 (https=)
CA (1) CA2882028C (https=)
ES (2) ES2837487T3 (https=)
SG (1) SG11201500799YA (https=)
WO (1) WO2014022423A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
DK3129487T3 (da) 2014-04-09 2020-11-30 Dna Twopointo Inc Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
US9808490B2 (en) * 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
US20220241345A1 (en) * 2015-10-02 2022-08-04 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
US12544406B2 (en) 2015-10-02 2026-02-10 The Regents Of The University Of California Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke
CA3001312A1 (en) 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
KR20230110373A (ko) * 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
BR112019001344A2 (pt) 2016-07-26 2019-04-30 The University Of North Carolina At Chapel Hill tolerância imunológica mediada por vetor no olho
WO2018132479A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Modified t cells and methods of their use
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
EP3731876A4 (en) * 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
JP7241161B2 (ja) 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
TW202043463A (zh) * 2018-12-14 2020-12-01 比利時商普羅米修亞生物科技股份有限公司 包含表現hla-e之肝先驅細胞之細胞組成物
TW202035682A (zh) 2018-12-14 2020-10-01 比利時商普羅米修亞生物科技股份有限公司 表現hla-g之肝先驅細胞及取得包含該等細胞之此等細胞組成物之方法與其用途
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
JP2023513263A (ja) * 2020-02-10 2023-03-30 ルビウス セラピューティクス， インコーポレイテッド Ｈｌａ－ｇポリペプチドを含む操作された赤血球系細胞およびその使用方法
WO2021241658A1 (ja) * 2020-05-26 2021-12-02 株式会社ヘリオス 低免疫原性細胞
EP4200023A4 (en) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113234664B (zh) * 2021-05-11 2024-05-10 澳门大学 一种胰腺祖细胞的制备方法及其应用
JP2024540987A (ja) * 2021-10-21 2024-11-06 バーテックス ファーマシューティカルズ インコーポレイテッド 低免疫細胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5534423A (en) 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5744320A (en) 1995-06-07 1998-04-28 Promega Corporation Quenching reagents and assays for enzyme-mediated luminescence
US6982431B2 (en) 1998-08-31 2006-01-03 Molecular Devices Corporation Sample analysis systems
US6031094A (en) 1998-07-23 2000-02-29 The Regents Of The University Of California Beta-lactam substrates and uses thereof
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
CN1302115C (zh) 2001-04-23 2007-02-28 埃麦克萨有限公司 电穿孔用缓冲溶液及上述溶液的使用方法
EP1543110A4 (en) 2002-05-17 2006-09-06 Sinai School Medicine POPULATION OF DEFINITIVE ENDODERMIC CELLS AND MESODERMAL
EP2341134B1 (en) 2003-01-31 2014-08-27 Promega Corporation Covalent tethering of functional groups to proteins
WO2005034624A2 (en) 2003-05-21 2005-04-21 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
PT1675956E (pt) * 2003-10-21 2010-11-04 Merck Serono Sa Sequência mínima de adn que actua como um isolador de cromatina e sua utilização na expressão de proteína
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
KR101271884B1 (ko) * 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CN103555655B (zh) * 2005-10-21 2018-02-27 细胞研究私人有限公司 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090156532A1 (en) * 2006-01-24 2009-06-18 The University Of Chicago SNP BINDING SITE FOR microRNAs IN HLA-G
WO2007091078A2 (en) * 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
EP2087107A2 (en) 2006-10-30 2009-08-12 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and functional expression
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
JP2012508591A (ja) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション 細胞を操作するための組成物および方法
US8592211B2 (en) 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
CN103333861A (zh) * 2013-06-03 2013-10-02 浙江省台州医院 特异性表达hla-g1抗原的细胞株k562
CN111808819A (zh) * 2020-05-26 2020-10-23 台州恩泽医疗中心(集团) 表达hla-g3异构体标准蛋白的细胞株及其应用

Also Published As

Publication number Publication date
AU2013296564C1 (en) 2019-01-17
KR20200136047A (ko) 2020-12-04
EP4015530A1 (en) 2022-06-22
KR102366081B1 (ko) 2022-02-23
KR20150038467A (ko) 2015-04-08
SG11201500799YA (en) 2015-03-30
AU2013296564A1 (en) 2015-02-26
CN105612176B (zh) 2021-01-19
JP7294838B2 (ja) 2023-06-20
KR102184947B1 (ko) 2020-12-01
EP2880054B1 (en) 2019-01-16
AU2018220087A1 (en) 2018-09-13
CA2882028C (en) 2023-11-07
CA2882028A1 (en) 2014-02-06
EP3805261A1 (en) 2021-04-14
AU2013296564B2 (en) 2018-06-28
JP2018088929A (ja) 2018-06-14
JP6502544B2 (ja) 2019-04-17
CN113151179A (zh) 2021-07-23
JP2021106601A (ja) 2021-07-29
EP3483178A1 (en) 2019-05-15
JP6297559B2 (ja) 2018-03-20
KR101923632B1 (ko) 2018-12-03
US20150158927A1 (en) 2015-06-11
AU2018220087B2 (en) 2020-05-14
EP2880054A4 (en) 2016-03-23
US10502738B2 (en) 2019-12-10
US20200041512A1 (en) 2020-02-06
WO2014022423A2 (en) 2014-02-06
US11977073B2 (en) 2024-05-07
US20170292952A1 (en) 2017-10-12
JP2015529457A (ja) 2015-10-08
EP3483178B1 (en) 2020-10-28
CN105612176A (zh) 2016-05-25
JP2019088334A (ja) 2019-06-13
US9714280B2 (en) 2017-07-25
KR102055438B1 (ko) 2019-12-19
WO2014022423A9 (en) 2015-09-03
JP7379410B2 (ja) 2023-11-14
KR20180128096A (ko) 2018-11-30
US20200309776A1 (en) 2020-10-01
ES2716577T3 (es) 2019-06-13
KR20190139319A (ko) 2019-12-17
EP2880054A2 (en) 2015-06-10
WO2014022423A3 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
ES2837487T3 (es) Métodos para producir células HLA-G modificadas
JP2022507453A (ja) Ｔ細胞送達のためのフソソーム組成物
US20250000912A1 (en) Hypoimmunogenic stem cells, hypoimmunogenic cells differentiated or derived from stem cells and method of preparing same
JP2019519239A (ja) 幹細胞由来移植片からの増殖性細胞の排除
HK40066059A (en) Hla-g transfected cells and their use in treating diabetes
HK40008748A (en) Methods to produce hla-g-modified cells
HK40008748B (en) Methods to produce hla-g-modified cells